Prognostic impact of CD133 expression in Endometrial Cancer Patients

Abstract

To assess the impact of CD133 expression on the prognosis of endometrioid endometrial carcinoma (EEC). We retrospectively assessed CD133 expression in tissue microarray of 116 surgically treated FIGO I-III EEC. Tumors with ≥10% of CD133-expressing cells were considered CD133-positive (CD133+). On the basis of CD133 expression, clinical and pathological parameters, progression-free survival (PFS) and overall survival (OS) were evaluated. Of the EEC studied 85.2% showed CD133-expressing cells. Only 61% (n = 66) of EEC presented ≥10% of CD133 expressing cells and were considered CD133+. The mean OS for CD133+ tumour patients was 161 months (95% CI, 154–168) as compared with 146 months (95% CI, 123–160) for those with CD133- tumors (p = 0.012). The mean PFS for CD133+ tumour was 159 months (95% CI, 149–168) as compared with 147 months (95% CI, 132-161) in those with a CD133-tumour (p = 0.014). CD133+ tumours were less likely to have vascular invasion (p = 0.010) and more likely to be well differentiated (p = 0.034). C133+ tumours predicted favorable OS and PFS of EEC patients, with a Hazard Ratio 4.731 (95% CI, 1.251–17.89; p = 0.022). CD133+ tumor status correlates with favorable prognosis of EEC. Our findings are in agreement with studies addressing brain and colorectal tumours.

Evaluation of Sialyl-Lactotetra as a Marker for Epithelial Ovarian Tumors

“…Although cancer stem cells are primarily considered within the context of a negative prognosis, the expression of stemcell markers and favorable outcomes has previously been described for various types of cancer (43)(44)(45). This includes ovarian carcinoma where higher levels of recognized ovarian cancer stem cell markers such as CD44 (46) and ALDH1 (36) were shown in association with extended progression-free and overall survival.…”

Expression of anti‑apoptotic protein survivin in human endometrial carcinoma: Clinical and pathological associations as a separate factor and in combination with concomitant PTEN and p53 expression

“…In every stained slide, the scores of immunohistochemical expression of survivin, p53 and PTEN, and their staining intensity was then combined to produce the final sum of immunohistochemical expression, which was classified into the following 4 categories: –, (0); +, ( 1 – 2 ); ++, ( 3 – 4 ); +++, ( 5 – 6 ).…”

“…Endometrioid adenocarcinomas also develop from endometrial hyperplasia in up to 80% of cases. The most common type II endometrial carcinoma is papillary serous adenocarcinoma, which is an oestrogen-independent neoplasm that develops in the atrophic endometrium, presents in elderly postmenopausal women and is associated with an aggressive behaviour and poor prognosis (3)(4)(5)(6)(7)(8).…”

“…Early-stage endometrial carcinomas result in favourable prognosis and excellent survival rates, with a 5-year overall survival of 75-90%. However, women with more advanced or recurrent disease tend to have an extremely poor clinical outcome, with a 5-year survival rate of only 10-30% (3)(4)(5)(6)(7)(8).…”

CD133 cells in endometrial cancer

“…Komórki CSCs zidentyfikowano zarówno w białaczkach, jak i w guzach litych. Charakterystyczną cechą CSCs jest zdolność do samoodnowy, różnicowania i migracji z pierwotnej masy do naczyń krwionośnych oraz innych narządów (8) . Zdolność do samoodnawiania prowadzi do INTRODUCTION E ndometrial cancer (EC) is one of the most common malignancies in women in developed countries and it is characterized by a constantly increasing morbidity.…”